Trending >

Byron analyst Douglas Loe maintains $8 target on IMRIS


Byron Capital Healthcare and Biotech analyst Douglas Loe says his aggressively positive view that IMRIS’s order flow can ramp up is based on the value proposition the company’s products offer to hospital clients, which he believes are more than compelling.On Thursday, IMRIS (TSX:IM) reported its Q2, 2912 results. The company lost $4.28-million on revenue of $17.2-million, which was down from $18.9-million in the same period last year.

Byron Capital Healthcare and Biotech analyst Douglas Loe says at this point in its history, investors should expect lumpy revenue from IMRIS.

Loe says he is instead focused on the company’s install base and backlog growth. He says this quarter showed strong magnetic resonance imaging system demand, and demand for the company’s integrated Visius systems is rising, too. In a research update to clients Friday, Loe maintained his BUY rating and $8 target on IMRIS.

__________________________

This story is brought to you by Agrimarine (TSXV:FSH). Not all salmon farms are the same. Click here to learn how Agrimarine is meeting consumer demand for sustainable aquaculture.

___________________________

Winnipeg-based IMRIS was founded in 1998 to commercialize research done by MRI pioneer Dr. Garnette Sutherland at the University of Calgary. The company, which now has forty-three patents either issued or pending, designs and manufactures Magnetic Resonance Imaging Systems for use in operating rooms. The company’s VISIUS Surgical Theatre can incorporate MR imaging, CT imaging and x-ray angiography in a number of configurations. While, at an estimated cost of between $4 and $12 million, they’re not cheap, the units do allow an MR or CT scanner to be shared by more than one clinical suite.

Loe says his aggressively positive view that IMRIS’s order flow can ramp up is based on the value proposition the company’s products offer to hospital clients, which he believes are more than compelling. The Byron analyst says he is encouraged to to hear that IMRIS’s ‘funnel’ of prospective orders (orders that are not yet in formal backlog, but have been made by client hospitals that have clear access to system funding and strong justification for purchase) remains strong.

Shares of IMRIS on the TSX closed Friday up 3.3% to $3.74.

___________________

__________________

  •  
  •  
  •  

About The Author /

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Comment

One thought on “Byron analyst Douglas Loe maintains $8 target on IMRIS

  1. It strikes me as interesting how IMRIS never mentions ANY competitors. I asked a neuro surgeon buddy of mine and found out the major MRI companies all offer inter-operative imaging solutions at half the cost of the IMRIS with the same safety and clinical outcomes.  Turns out Siemens, Phillips and GE have a greater installed base than IMRIS. Hard to justify double the cost for similar technology. What am I missing here???    

Leave a Reply

Your email address will not be published. Required fields are marked *